In vitro characterization of some biopharmaceutical properties of praziquantel

International Journal of Pharmaceutics

Volumn 295, Issue 1-2, 2005, Pages 93-99

  Dinora, González Esquivel ^a   Julio, Rivera ^b   Nelly, Castro ^a   Lilian, Yepez Mulia ^c   Cook, Helgi Jung ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Caco 2 cells; Dissolution; Milk; Official media; Permeability; Physiological media; Praziquantel; Protein binding

Indexed keywords

DODECYL SULFATE SODIUM; PHOSPHATIDYLCHOLINE; PRAZIQUANTEL; TAUROCHOLIC ACID;

ARTICLE; CELL STRAIN CACO 2; DIET RESTRICTION; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE FLUID; MILK; NEUROCYSTICERCOSIS; PRIORITY JOURNAL; TABLET FORMULATION;

EID: 17644379014     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.01.033     Document Type: Article

References (15)

1. P.R.M. Bittencourt, C.M. Gracia, and R. Martins Phenytoin and carbamazepine decrease oral bioavailability of praziquantel Neurology 42 1992 492 496
2. N. Castro, R. Medina, J. Sotelo, and H. Jung Bioavailability increases with concomitant administration of food Antimicrob. Agents Chemoter. 44 2000 2903 2904
3. E. Galia, E. Nicolaides, C. Reppas, and J.B. Dressman New media discriminate dissolution of poorly soluble drugs Pharm. Res. 13 1996 S-262
4. D.F. González-Esquivel, O.C. Morano, R.M. Sánchez, M.J. Sotelo, and C.H. Jung Sensitive high-performance liquid chromatographic assay for praziquantel in plasma, urine and liver homogenates J. Chromatogr. 613 1993 174 178
5. G.M. Grass, and S.A. Sweetana A correlation of permeabilities for passively transported compounds in monkey and rabbit jejunum Pharm. Res. 6 1989 857 862
6. H. Jung, M. Hurtado, M. Sanchez, T.M. Medina, and J. Sotelo Plasma and CSF levels of albendazol and praziquantel in patients with neuroysticercosis Clin. Neuropharm. 13 1990 559 564
7. O.H. Lowry, N.J. Rosebrough, A.I. Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
8. A.J. McLean, C. Isbister, A. Bobik, and F.J. Dudley Reduction of first pass hepatic clearance of propranolol by food Clin. Pharmacol. Ther. 30 1981 31 34
9. E. Nicolaides, E. Galia, C. Efthymiopoulos, B.J. Dressman, and C. Reppas Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data Pharm. Res. 16 1999 1876 1882
10. K. Patzschke, J. Putter, A.F. Wegner, and W.H. Diekmann Serum concentrations and renal excretion in humans after oral administration of praziquantel-results of three determination methods Eur. J. Drug Metab. Pharmacokinet. 3 1979 149 156
11. E. Rinaki, V. Georgia, and M. Pano Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio Pharm. Res. 20 2003 1917 1924
12. P.M. Sathe, Y. Tsong, and V.P. Shah In vitro dissolution profile comparison: statistics ans analysis, model dependent approach Pharm. Res. 13 1996 1799 1803
13. J. Sotelo, O.H. del Brutto, P. Penagos, F. Escobedo, B. Torres, J. Rodriguez-Carbajal, and F. Rubio-Donnadieu Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis J. Neurol. 237 1990 69 72
14. M. Yazdanian, L.S. Glynn, L.J. Wright, and A. Hawi Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds Pharm. Res. 15 1998 1490 1494
15. N. Yuksel, A.E. Kanik, and T. Baykara Comparision of in vitro dissolution profiles by ANOVA-based, model-dependent and independent methods Int. J Pharm. 209 2000 57 67